Motavizumab - Next gen biotech blockbusters

Drug: Motavizumab
Company: MedImmune/AstraZeneca

Scoop: When AstraZeneca spent $15.6 billion to acquire MedImmune, it picked up motavizumab in the process. Motavizumab, to be sold as Numax, is a fully humanized monoclonal antibody to prevent respiratory syncytial virus infection in infants--a condition which sends about 125,000 infants to the hospital each year. A BLA was submitted back in February and an FDAdecision is expected sometime this year.

Motavizumab - Next gen biotech blockbusters

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.